Brief: Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer

NovoCure

31/05/2025 13:07

May 31 (Reuters) - Novocure Ltd NVCR.O:

RESULTS FROM THE PHASE 3 PANOVA-3 TRIAL OF NOVOCURE’S TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR PANCREATIC CANCER TO BE PRESENTED AT 2025 ASCO ANNUAL MEETING

NOVOCURE LTD - TTFIELDS THERAPY SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR PANCREATIC CANCER

NOVOCURE LTD - TO FILE FOR FDA APPROVAL OF TTFIELDS THERAPY IN H2 2025

NOVOCURE LTD - PANOVA-3 TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN MEDIAN OS

NOVOCURE LTD - TTFIELDS THERAPY IMPROVES ONE-YEAR SURVIVAL RATE TO 68.1%

Source text: ID:nBw9c5fT5a

Further company coverage: NVCR.O

 ((Reuters.Briefs@thomsonreuters.com;))